Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.

In tandem with Enhertu’s inclusion in China’s national insurance program, Daiichi Sankyo is planting a foothold in local ...

The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists ...

Toshinori Agatsuma, head of research at Daiichi Sankyo, has died. He led development of ADC technology behind breast cancer ...

Daiichi Sankyo Company is making significant strides in the pharmaceutical industry, evidenced by its financial growth and strategic collaborations, such as with Merck on MK-6070. The company is set ...

The government's drug funding agency Pharmac is asking for public feedback on its proposal to fund four new medicines for ...

Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...

One in nine New Zealand women get breast cancer in their lifetimes, and around 16% of metastatic breast cancers are ...

Pharmac will also fund osimertinib for people with a type of advanced non-small cell lung cancer. About 20 percent of people with non-small cell lung cancer have a mutation in their cancer that can be ...

HER2-positive advanced cancer patients will have access to game-changing drug Enhertu . It can boost the time the cancer's held at bay - from 7 months to more than 2 years. CEO Ah-Leen Rayner says ...